FDA lifts tgAAC94 hold

Targeted Genetics (TGEN) said FDA lifted the clinical hold on a Phase I/II trial of tgAAC94 to treat inflammatory arthritis. The trial was put on hold in July when a woman died. Earlier this month, TGEN said final molecular test results confirmed that tgAAC94 did not contribute to the patient's death and that the cause of death was disseminated histoplasmosis and a severe retroperitoneal hematoma (See BioCentury Extra, Monday, Nov. 12, 2007). ...